Speakers - 2026

Title: Artificial Intelligence Assisted Early Detection of Parkinson’s Disease Using Voice Biomarkers: Emerging Diagnostic Opportunities in Modern Neurology

Abstract

Description of Presentation:

Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide and represents a growing clinical and public health challenge as populations age. Despite important therapeutic advances, diagnosis remains primarily clinical and frequently occurs only after substantial dopaminergic neuronal loss has already taken place. Earlier recognition is increasingly important as research shifts toward neuroprotective strategies, earlier symptomatic intervention, and personalized disease management. However, scalable, low-cost, and accessible early screening tools remain limited, particularly in community settings, lower-resource healthcare systems, and regions with reduced access to specialist neurology services.

Speech dysfunction is increasingly recognized as one of the earliest measurable manifestations of Parkinson’s disease. Subtle abnormalities in vocal intensity, articulation, fluency, pitch variability, prosody, phonatory stability, pause patterns, and speech rhythm may emerge before pronounced motor impairment becomes clinically obvious. These changes are often difficult to quantify during routine consultations, creating an opportunity for objective digital analysis.

Recent advances in artificial intelligence (AI), machine learning, and digital biomarker science have enabled rapid automated evaluation of short voice recordings using acoustic and linguistic features. Algorithms such as support vector machines, random forests, gradient boosting models, convolutional neural networks, recurrent neural networks, and transformer-based systems have shown promising performance in distinguishing individuals with Parkinson’s disease from healthy controls and, in some studies, identifying early-stage disease patterns.

This presentation will provide a clinically focused and evidence-based review of the current landscape of AI-assisted voice biomarker detection in Parkinson’s disease. Key speech features, commonly used datasets, comparative strengths of major algorithmic approaches, and reported diagnostic performance metrics will be summarized in a practical format relevant to clinicians, researchers, and trainees. Particular attention will be given to the translational potential of smartphone-based screening tools, remote monitoring platforms, wearable ecosystem integration, and tele-neurology pathways that may help shorten time to specialist assessment.

The session will also critically address important barriers to implementation, including limited external validation, small and homogeneous datasets, language and accent variability, risk of algorithmic bias, privacy concerns, reproducibility challenges, regulatory uncertainty, and the need to avoid replacing expert clinical judgment. Emphasis will be placed on responsible adoption in which AI functions as an adjunctive tool that enhances, rather than substitutes for, neurological assessment.

As neurology enters an era increasingly shaped by precision medicine and digital diagnostics, AI-enabled voice analysis may become one of the most scalable and patient-friendly opportunities for earlier Parkinson’s disease detection. This presentation offers attendees a timely, balanced, and practice-oriented overview of a rapidly evolving field with significant implications for movement disorders, outpatient neurology pathways, and future models of accessible neurological care.

Key Takeaways:

• Early Voice Biomarkers in Parkinson’s Disease: How subtle speech changes may help identify Parkinson’s disease earlier.
• AI in Clinical Neurology: How machine learning can analyze voice recordings to support diagnosis.
• Real-World Applications: Use of smartphone screening, tele-neurology, and remote monitoring tools.
• Current Limitations: Understanding bias, validation challenges, privacy concerns, and implementation barriers.
• Future Opportunities: Research, education, and innovation in digital neurology.

How the Audience Will Be Able to Use What They Learn:

• Clinicians can apply this knowledge to recognize early speech changes that may warrant earlier neurological referral or further evaluation.
• Neurologists and trainees can stay current with rapidly developing AI tools likely to influence future clinical workflows.
• Researchers and faculty can use the presented evidence to develop new studies, student projects, or teaching modules focused on digital biomarkers and neurodegenerative disease.
• Healthcare leaders may identify scalable screening approaches that improve access to specialist care in resource-limited or rural settings.
• Medical educators can integrate these concepts into neuroscience, neurology, and AI-in-medicine curricula.

Professional and Practical Benefits:

• Supports earlier recognition of Parkinson’s disease.
• Encourages evidence-based adoption of emerging technology.
• Improves awareness of digital neurology innovations.
• Provides practical strategies for remote patient assessment.
• Stimulates collaborative research across medicine, engineering, and data science.
• Helps prepare healthcare professionals for the future of precision neurological care.